Warning! GuruFocus detected
2 Severe warning signs
with CYC.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cyclopharm Ltd
NAICS : 334510
SIC : 3845
ISIN : AU000000CYC5
Compare
Compare
Traded in other countries / regions
CYC.Australia IPO Date
2007-01-18Description
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.48 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -0.72 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.72 | |||||
| Beneish M-Score | -2.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | -40.9 | |||||
| 3-Year EPS without NRI Growth Rate | -31.7 | |||||
| 3-Year FCF Growth Rate | -62.1 | |||||
| 3-Year Book Growth Rate | -5.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 49.63 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.92 | |||||
| 9-Day RSI | 40.96 | |||||
| 14-Day RSI | 38.3 | |||||
| 3-1 Month Momentum % | -14.06 | |||||
| 6-1 Month Momentum % | -16.16 | |||||
| 12-1 Month Momentum % | -23.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.99 | |||||
| Quick Ratio | 2.75 | |||||
| Cash Ratio | 1.94 | |||||
| Days Inventory | 426.11 | |||||
| Days Sales Outstanding | 84.09 | |||||
| Days Payable | 188.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | -17.82 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.04 | |||||
| Operating Margin % | -52.68 | |||||
| Net Margin % | -47.87 | |||||
| FCF Margin % | -49.13 | |||||
| ROE % | -32.31 | |||||
| ROA % | -23 | |||||
| ROIC % | -48.83 | |||||
| 3-Year ROIIC % | -48.03 | |||||
| ROC (Joel Greenblatt) % | -65.44 | |||||
| ROCE % | -27.52 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 2.13 | |||||
| PS Ratio | 4.61 | |||||
| PB Ratio | 3.23 | |||||
| Price-to-Tangible-Book | 3.76 | |||||
| EV-to-EBIT | -9.93 | |||||
| EV-to-EBITDA | -11.2 | |||||
| EV-to-Revenue | 4.69 | |||||
| EV-to-Forward-Revenue | 6.66 | |||||
| EV-to-FCF | -9.68 | |||||
| Price-to-GF-Value | 0.57 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 5.9 | |||||
| Price-to-Net-Cash | 124 | |||||
| Earnings Yield (Greenblatt) % | -10.07 | |||||
| FCF Yield % | -9.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyclopharm Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 27.573 | ||
| EPS (TTM) (A$) | -0.128 | ||
| Beta | 2.09 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 71.99 | ||
| 14-Day RSI | 38.3 | ||
| 14-Day ATR (A$) | 0.097428 | ||
| 20-Day SMA (A$) | 1.3195 | ||
| 12-1 Month Momentum % | -23.61 | ||
| 52-Week Range (A$) | 1.1 - 2.5 | ||
| Shares Outstanding (Mil) | 111.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyclopharm Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyclopharm Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyclopharm Ltd Frequently Asked Questions
What is Cyclopharm Ltd(ASX:CYC)'s stock price today?
The current price of ASX:CYC is A$1.24. The 52 week high of ASX:CYC is A$2.50 and 52 week low is A$1.10.
When is next earnings date of Cyclopharm Ltd(ASX:CYC)?
The next earnings date of Cyclopharm Ltd(ASX:CYC) is .
Does Cyclopharm Ltd(ASX:CYC) pay dividends? If so, how much?
Cyclopharm Ltd(ASX:CYC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers